当地时间2024年9月13日-17日，备受关注的2024欧洲肿瘤内科学会（ESMO）年会将于在西班牙巴塞罗那盛大召开。ESMO大会将一如既往为肿瘤领域带来最新前沿进展与诊疗理念，为改变临床实践、探索研究风向等提供学术交流平台。当前，ESMO官网已公布了入选本届年会的LBA摘要标题，【肿瘤资讯】整理了消化道肿瘤领域的优选口头报告（Proffered Paper session）和迷你口头报告（Mini Oral session）部分的LBA研究，带您一睹为快！
Proffered Paper session1：上消化道肿瘤
摘要号：LBA38
英文标题：Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy in first-line (1L) treatment of advanced hepatocellular carcinoma (aHCC): a randomized, open-label, phase 2/3 study (DUBHE-H-308)
中文标题：Iparomlimab和tuvonralimab（QL1706）联合贝伐珠单抗和/或化疗用于晚期肝细胞癌（aHCC）一线（1L）治疗：一项随机、开放标签、2/3期研究（DUBHE-H-308）
讲者：秦叔逵 中国药科大学附属南京天印山医院
摘要号：LBA39
英文标题：Updated efficacy and safety data from IMbrave050: Phase 3 study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC)
中文标题：IMbrave050研究疗效和安全性数据更新：在切除或消融的高危肝细胞癌（HCC）患者中，辅助阿替利珠单抗（atezo） + 贝伐珠单抗（bev）vs主动监测的3期研究
讲者：Adam Yopp (Dallas, United States of America)
摘要号：LBA62
英文标题：Preoperative modified FOLFIRINOX (mFOLFIRINOX) with or without chemoradiation (CRT) in borderline resectable pancreatic cancer (BRPC): results from the randomized phase II trial PANDAS/PRODIGE 44
中文标题：术前改良FOLFIRINOX（mFOLFIRINOX）伴或不伴放化疗（CRT）治疗边缘性可切除胰腺癌（BRPC）:来自随机II期试验PANDAS/PRODIGE 44的结果
讲者：Aurélien Lambert (Nancy, France)
摘要号：LBA40
英文标题：Primary results from the phase III ALTN-AK105-III-02 study: Anlotinib plus penpulimab versus sorafenib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)
中文标题：III期ALTN-AK105-III-02研究主要结果：安罗替尼+ 派安普利单抗对比索拉非尼作为晚期肝细胞癌（aHCC）一线治疗
讲者：周俭 复旦大学附属中山医院
Proffered Paper session2：上消化道肿瘤
摘要号：LBA58
英文标题：A randomized phase III trial of perioperative chemotherapy (periop CT) with or without preoperative chemoradiotherapy (preop CRT) for resectable gastric cancer (AGITG TOPGEAR): final results from an intergroup trial of AGITG, TROG, EORTC and CCTG
中文标题：可切除胃癌围手术期化疗加或不加术前放化疗的随机III期试验（AGITG TOPGEAR）：AGITG、TROG、EORTC和CCTG组间试验的最终结果
讲者：Trevor Leong (Melbourne, Australia)
摘要号：LBA59
英文标题：Modified FOLFOX plus/minus Nivolumab and Ipilimumab vs FLOT plus Nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction – Final Results of the IKF-AIO-Moonlight trial
中文标题：改良FOLFOX±纳武利尤单抗和伊匹木单抗对比FLOT联合纳武利尤单抗治疗既往未经治晚期或转移性胃或胃食管交界处腺癌患者——IKF-AIO-Moonlight试验的最终结果
讲者：Sylvie Lorenzen (Munich, Germany)
Mini Oral session：上消化道肿瘤
摘要号：LBA60
英文标题：Phase 3 study of SHR-1701 versus placebo in combination with chemo as first-line (1L) therapy for HER2-negative gastric/gastroesophageal junction adenocarcinoma (G/GEJA)
中文标题：SHR-1701对比安慰剂联合化疗作为HER2阴性胃/胃食管交界处腺癌（G/GEJA）一线治疗的3期研究
讲者：彭智 北京大学肿瘤医院
摘要号：LBA63
英文标题：A randomized phase I/II study of second line treatment with liposomal irinotecan and S-1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer following gemcitabine-based chemotherapy
中文标题：在吉西他滨为基础化疗后的转移性胰腺癌患者中，采用伊立替康脂质体联合S-1对比伊立替康脂质体联合氟尿嘧啶二线治疗的一项随机I/II期研究
讲者：Anne M. Gehrels (Amsterdam, Netherlands)
Proffered Paper session1：下消化道肿瘤
摘要号：LBA24
英文标题：Neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer: 3-year disease-free survival from NICHE-2
中文标题：局部晚期dMMR结肠癌的新辅助免疫治疗:NICHE-2研究3年无病生存
讲者：Myriam Chalabi (Amsterdam, Netherlands)
Proffered Paper session2：下消化道肿瘤
摘要号：LBA25
英文标题：Randomized Phase III trial of Ramucirumab in combination with TAS102 (Trifluridin/Tipiracil) vs. TAS102 monotherapy in heavily pretreated metastatic colorectal cancer: The RAMTAS/IKF643 trial of the German AIO (AIO-KRK-0316)
中文标题：雷莫西尤单抗联合TAS-102（曲氟尿苷替匹嘧啶）对比TAS102单药治疗重度预处理转移性结直肠癌的随机III期试验：德国AIO (AIO- krk -0316) RAMTAS/IKF643试验
讲者：Stefan Kasper-Virchow (Essen, Germany)
摘要号：LBA26
英文标题：SOLARIS (Alliance A021703): A multicenter double-blind phase III randomized clinical trial (RCT) of vitamin D (VitD) combined with standard chemotherapy plus bevacizumab (bev) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC)
中文标题：SOLARIS（Alliance A021703）：一项多中心双盲III期随机临床试验，采用维生素D联合标准化疗+贝伐珠单抗治疗先前未经治疗的转移性结直肠癌（mCRC）患者
讲者：Kimmie Ng (Boston, United States of America)
https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session
排版编辑：肿瘤资讯-AS
苏公网安备 32059002004080号
